Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population

Leif Bjermer,Job F. M. van Boven,Madlaina Costa-Scharplatz,Dorothy L. Keininger,Florian S. Gutzwiller,Karin Lisspers,R Mahon,Petter Olsson,Nicolas Roche

Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population

2017

Leif Bjermer
Job F. M. van Boven
Madlaina Costa-Scharplatz
Dorothy L. Keininger
Florian S. Gutzwiller
Karin Lisspers
R Mahon
Petter Olsson
Nicolas Roche

Background This study assessed the cost-effectiveness of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with moderate to very severe airflow limitation and ≥1 exacerbation in the preceding year.

Keywords:

Immunology
Indacaterol
Salmeterol
Fluticasone
Population
Internal medicine
Exacerbation
COPD
Salmeterol fluticasone
Medicine
health outcomes
swedish population

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations